ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
08 May 2012 - 8:30PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops targeted antibody-based anticancer products, today
announced that the following presentations by Company management at
upcoming investor conferences will be webcast:
Bank of America Merrill Lynch 2012 Health Care
Conference8:40 am PT (11:40 am ET) on May 16, 2012 in Las
Vegas, NVPresenter: Gregory Perry, Executive Vice President and
CFO
Jefferies 2012 Global Healthcare Conference9:30 am ET on
June 6, 2012 in New York, NYPresenter: Daniel Junius, President and
CEO
The webcast of each presentation can be accessed live through
the "Investor Information" section of the Company's website,
www.immunogen.com; a replay of each presentation will be available
at the same location for one week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
the Company's expertise in tumor biology, monoclonal antibodies,
potent cancer-cell killing agents and engineered linkers. The
Company's Targeted Antibody Payload (TAP) technology uses
monoclonal antibodies to deliver one of ImmunoGen's proprietary
cancer-cell killing agents specifically to tumor cells. There are
now numerous TAP compounds in clinical development with a wealth of
clinical data reported. ImmunoGen's collaborative partners include
Amgen, Bayer HealthCare, Biotest, Lilly, Novartis, Roche, and
Sanofi. The most advanced compound using ImmunoGen's TAP
technology, trastuzumab emtansine (T-DM1), is in Phase III testing
through the Company's collaboration with Genentech, a member of the
Roche Group. More information about ImmunoGen can be found at
www.immunogen.com.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024